Non peptide heterobivalent molecules for treating inflammatory diseases
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsJames BAILEY, Yao CHEN, Mark HURLE, Craig LEACH, Brandon TURUNEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to non peptidic, heterobivalent molecules (HBM) that are able to simultaneously bind a surface target protein as well as an endogenous or exogenous human antibody protein and induce immune effector function. More specifically, the present invention relates to agents capable of binding to a chemokine receptor and inducing the depletion of chemokine receptor positive subsets of pathogenic cells in a subject for use in the treatment and/or prevention of cancer, inflammatory, autoimmune and allergic disease.
Claims14
A method of destroying CCR-positive cells in a human using a Heterobivalent Molecule (HBM), wherein HBM comprise a moiety binding to a CCR receptor on the cell and a moiety binding to endogenous or exogenous antibodies.
A method of treating or preventing cancers, inflammatory disease, autoimmune disease, or allergic disease in a human patient comprising administering a therapeutically effective amount of HBM to the human patient.
A pharmaceutical composition comprising HBM and one or more pharmaceutically acceptable excipients, carriers, and/or diluents.
Dependencies are inferred from the claim text.